232 related articles for article (PubMed ID: 9540025)
1. Chronic treatment of African-American type 2 diabetic patients with alpha-glucosidase inhibition.
Johnston PS; Feig PU; Coniff RF; Krol A; Kelley DE; Mooradian AD
Diabetes Care; 1998 Mar; 21(3):416-22. PubMed ID: 9540025
[TBL] [Abstract][Full Text] [Related]
2. Long-term titrated-dose alpha-glucosidase inhibition in non-insulin-requiring Hispanic NIDDM patients.
Johnston PS; Feig PU; Coniff RF; Krol A; Davidson JA; Haffner SM
Diabetes Care; 1998 Mar; 21(3):409-15. PubMed ID: 9540024
[TBL] [Abstract][Full Text] [Related]
3. Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients.
Johnston PS; Lebovitz HE; Coniff RF; Simonson DC; Raskin P; Munera CL
J Clin Endocrinol Metab; 1998 May; 83(5):1515-22. PubMed ID: 9589648
[TBL] [Abstract][Full Text] [Related]
4. Dose-dependent efficacy of miglitol, an alpha-glucosidase inhibitor, in type 2 diabetic patients on diet alone: results of a 24-week double-blind placebo-controlled study.
Drent ML; Tollefsen AT; van Heusden FH; Hoenderdos EB; Jonker JJ; van der Veen EA
Diabetes Nutr Metab; 2002 Jun; 15(3):152-9. PubMed ID: 12173729
[TBL] [Abstract][Full Text] [Related]
5. The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone.
Segal P; Feig PU; Schernthaner G; Ratzmann KP; Rybka J; Petzinna D; Berlin C
Diabetes Care; 1997 May; 20(5):687-91. PubMed ID: 9135927
[TBL] [Abstract][Full Text] [Related]
6. Effects of the carbohydrase inhibitor miglitol in sulfonylurea-treated NIDDM patients.
Johnston PS; Coniff RF; Hoogwerf BJ; Santiago JV; Pi-Sunyer FX; Krol A
Diabetes Care; 1994 Jan; 17(1):20-9. PubMed ID: 8112185
[TBL] [Abstract][Full Text] [Related]
7. Long-term effectiveness of a new alpha-glucosidase inhibitor (BAY m1099-miglitol) in insulin-treated type 2 diabetes mellitus.
Mitrakou A; Tountas N; Raptis AE; Bauer RJ; Schulz H; Raptis SA
Diabet Med; 1998 Aug; 15(8):657-60. PubMed ID: 9702468
[TBL] [Abstract][Full Text] [Related]
8. Does suppression of postprandial blood glucose excursions by the alpha-glucosidase inhibitor miglitol improve insulin sensitivity in diet-treated type II diabetic patients?
Johnson AB; Taylor R
Diabetes Care; 1996 Jun; 19(6):559-63. PubMed ID: 8725851
[TBL] [Abstract][Full Text] [Related]
9. The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes.
Chiasson JL; Naditch L;
Diabetes Care; 2001 Jun; 24(6):989-94. PubMed ID: 11375358
[TBL] [Abstract][Full Text] [Related]
10. [The alpha-glucosidase inhibitor miglitol for the treatment of type 2 diabetes mellitus in the doctor's office].
Fehmann HC
Fortschr Med Orig; 2001 Jul; 119 Suppl 2():55-61. PubMed ID: 15704357
[TBL] [Abstract][Full Text] [Related]
11. Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus.
Scott LJ; Spencer CM
Drugs; 2000 Mar; 59(3):521-49. PubMed ID: 10776834
[TBL] [Abstract][Full Text] [Related]
12. Comparison of miglitol and glibenclamide in diet-treated type 2 diabetic patients.
Pagano G; Marena S; Corgiat-Mansin L; Cravero F; Giorda C; Bozza M; Rossi CM
Diabete Metab; 1995 Jun; 21(3):162-7. PubMed ID: 7556806
[TBL] [Abstract][Full Text] [Related]
13. Miglitol combined with metformin improves glycaemic control in type 2 diabetes.
Van Gaal L; Maislos M; Schernthaner G; Rybka J; Segal P
Diabetes Obes Metab; 2001 Oct; 3(5):326-31. PubMed ID: 11703422
[TBL] [Abstract][Full Text] [Related]
14. Improved glycaemic control with miglitol in inadequately-controlled type 2 diabetics.
Standl E; Schernthaner G; Rybka J; Hanefeld M; Raptis SA; Naditch L
Diabetes Res Clin Pract; 2001 Mar; 51(3):205-13. PubMed ID: 11269893
[TBL] [Abstract][Full Text] [Related]
15. alpha-Glucosidase inhibition by miglitol in NIDDM patients.
Kingma PJ; Menheere PP; Sels JP; Nieuwenhuijzen Kruseman AC
Diabetes Care; 1992 Apr; 15(4):478-83. PubMed ID: 1499461
[TBL] [Abstract][Full Text] [Related]
16. Effects of 8-wk alpha-glucosidase inhibition on metabolic control, C-peptide secretion, hepatic glucose output, and peripheral insulin sensitivity in poorly controlled type II diabetic patients.
Schnack C; Prager RJ; Winkler J; Klauser RM; Schneider BG; Schernthaner G
Diabetes Care; 1989 Sep; 12(8):537-43. PubMed ID: 2673693
[TBL] [Abstract][Full Text] [Related]
17. Miglitol, a new alpha-glucosidase inhibitor.
Sels JP; Huijberts MS; Wolffenbuttel BH
Expert Opin Pharmacother; 1999 Nov; 1(1):149-56. PubMed ID: 11249557
[TBL] [Abstract][Full Text] [Related]
18. The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics.
Lee A; Patrick P; Wishart J; Horowitz M; Morley JE
Diabetes Obes Metab; 2002 Sep; 4(5):329-35. PubMed ID: 12190996
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of type 2 diabetes mellitus with the alpha-glucosidase inhibitor Miglitol in the doctor's office].
Fehmann HC
Fortschr Med Orig; 2000 Jul; 118 Suppl 2():55-61. PubMed ID: 15700487
[TBL] [Abstract][Full Text] [Related]
20. Miglitol: assessment of its role in the treatment of patients with diabetes mellitus.
Campbell LK; Baker DE; Campbell RK
Ann Pharmacother; 2000 Nov; 34(11):1291-301. PubMed ID: 11098345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
